Good News on Listing | Frost & Sullivan Assists Beijing Huahao Zhongtian Biopharmaceutical Co., Ltd. to Successfully List on the Hong Kong Stock Exchange (2563.HK)

Beijing Huahao Zhongtian Biopharmaceutical Co., Ltd. (hereinafter referred to as 'Huahao Zhongtian') successfully went public on October 31, 2024. The company plans to issue 1,458.8 million H shares, including 1.7506 million shares for Hong Kong and 12.8374 million shares for international issuance. The issue price per share is HK$16.0, raising a net amount of approximately HK$230 million.

During the process of listing in Hong Kong this time, Frost & Sullivan mainly undertook the following tasks: helping the issuer accurately and objectively understand its positioning in the target market, using objective market data to discover, support, and highlight the issuer's competitive advantages, assisting the issuer, investment banks, and other intermediaries in completing the relevant parts of the prospectus (such as overview, competitive advantages and strategy, industry overview, business, and other important chapters), facilitating communication between the issuer and the Exchange and investors, helping investors quickly understand the market ecosystem and competitive landscape, and assisting the issuer in completing feedback on various industry-related issues from the Exchange.

• The company is a biopharmaceutical company driven by synthetic biology technology, dedicated to developing innovative oncology drugs;

   

• The company has established three key technology platforms based on synthetic biology, including the combinatorial biosynthesis platform, the microbial large-scale fermentation production technology platform, and the microbial drug formulation development platform;

   

• Possesses one commercialized product (Yutide Long Injection) and 19 other pipeline candidate products;

   

• The company's product, Ustekinumab Injection, is the only chemotherapy drug developed through synthetic biology technology and approved for marketing. It is also the only microtubule inhibitor of tumor type with a novel molecular structure approved globally since 2010.

   

• In 2023, the market size of microtubule inhibitors in China reached 8.1 billion RMB, and it is expected that the market size of microtubule inhibitors will continue to grow at a rate of 15.4% over the next four years in China.

Yutidelong injection has been approved by the National Medical Products Administration for the treatment of patients with recurrent or metastatic breast cancer who have received at least one anthracycline or taxane chemotherapy regimen and are treated in combination with capecitabine. It is also included in the national medical insurance drug list for the treatment of recurrent or metastatic breast cancer patients who have previously received at least one chemotherapy regimen, but its use is not limited to the treatment of specific subtypes of advanced breast cancer.

Market size of breast cancer drugs in China and globally from 2018 to 2030 (estimated):

Source: Frost & Sullivan report

According to a Frost & Sullivan report, the global market size for breast cancer drugs reached $382 billion in 2023, with a compound annual growth rate of 7.4% from 2018 to 2023. In 2023, the market size for breast cancer drugs in China reached $84 billion, with a compound annual growth rate of 6.8% from 2018 to 2023. It is estimated that by 2030, the global market size for breast cancer drugs will reach $641 billion, of which the market size for breast cancer drugs in China will reach $156 billion.

The market size of non-small cell lung cancer drugs in China and globally from 2018 to 2030 (estimated):

Source: Frost & Sullivan report

Lung cancer is one of the leading causes of cancer-related deaths in China and globally. NSCLC is the most common type of lung cancer, accounting for about 85% of all lung cancer cases. According to a Frost & Sullivan report, the global market size for non-small cell lung cancer drugs reached $78.3 billion in 2023, with a compound annual growth rate of 11.9% from 2018 to 2023. In 2023, the market size for non-small cell lung cancer drugs in China reached $8.8 billion, with a compound annual growth rate of 17.8% from 2018 to 2023. It is estimated that by 2030, the global market size for non-small cell lung cancer drugs will reach $165.1 billion, with the market size in China reaching $22.6 billion.

According to a Frost & Sullivan report, as of May 31, 2024, there are 22 drug candidates for breast cancer that are in the same stage or later stages of clinical trials, including 18 from China. Globally, seven microtubule inhibitor chemotherapy drugs have been approved for the treatment of breast cancer, and the National Medical Products Administration has approved a total of five breast cancer microtubule inhibitors (including eight dosage forms).

Analysis of microtubule inhibitors approved for the treatment of breast cancer in China (including different dosage forms):

Source: Frost & Sullivan report

Frost & Sullivan, integrating 63 years of global consulting experience, has dedicated 26 years to serving the booming Chinese market. With a global perspective, it helps clients accelerate their business growth, achieving benchmark positions in industry growth, innovation, and leadership. The healthcare industry is one of the core areas of focus for Frost & Sullivan. Over the past 20-plus years, the Frost & Sullivan team has provided financing and financial advisory services, IPO industry advice, strategic consulting, management consulting, and other services to hundreds of outstanding domestic and international biopharmaceutical, medical device, healthcare services, and internet healthcare companies. Successful listings include: Yinos (688710.SH), Jingtai Technology (2228.HK), Yimai Sunshine (2522.HK), Shenghe Biotech (2898.HK), Quanxin Biotech (2509.HK), Meizhong Jiahe (2453.HK), WuXi AppTec (2268.HK), Anol Medical (NASDAQ:ANL), Neusoft Xikang (9686.HK), Youzhiyou (2496.HK), Yiming Angke (1541.HK), Corning Biotech (6990.HK), LaiKai Medical (2105.HK), Kedai Group (2487.HK), Lvtu Biotech (2480.HK), Meis Health (2415.HK), PHECR, Zhongjin Medical (NASDAQ:ZJYL), Yisheng Biotech (NASDAQ:YS), Meili Tianyuan (2373.HK), Kangfeng Biotech (6922.HK), Bao'an Biotech (6955.HK), Sididi (1244.HK), Meihao Medical (1947.HK), Gaosheng Medical (2407.HK), Lepu Xintai (2291.HK), Jianshi Technology (9877.HK), Health Yuan (JCARE.SW), Lepu Medical (LEPU.SW), Dingdang Health (9886.HK), Biotec (2315.HK), Zhiyun Health (9955.HK), MeinGene (6667.HK), Prenetics (PRE.NASDAQ), Yunkang Group (2325.HK), Rike Biotech (2179.HK), Lepu Biotech (2157.HK), Clear Medical (1406.HK), Baxin An (2185.HK), Yonghe Medical (2279.HK), Kailaiying (6821.HK), Beihai Kangcheng (1228.HK), Gusheng Tang (2273.HK), Yingpeng Technology (2251.HK), Clover Biotech (2197.HK), Minimally Invasive Robotics (2252.HK), Harmony Kamane (2256.HK), Kunbo Medical (2216.HK), Xianruida (6669.HK), Kangsheng Global (9960.HK), Yimai Tong (2192.HK), Tengsheng Bowa (2137.HK), Canora (2162.HK), Chaoyu Ophthalmology (2219.HK), Guichuang Tongqiao (2190.HK), Hehuang Medicine (0013.HK), Koji Pharmaceutical (2171.HK), Zhaoke Ophthalmology (6622.HK), Nature Pharmacy (UPC.NASDAQ), Saiseng Pharmaceutical (6600.HK), Zhaoyan New Drugs (6127.HK), Novogene Health (6606.HK), ADAG.NASDAQ, Beikang Medical (2170.HK), Jianbimiao Miao (2161.HK), Minimally Invasive Heart Link (2160.HK), Rui Li Medical Beauty (2135.HK), Jiaosisi Pharmaceutical (1167.HK), HepB Pharma (2142.HK), JD Health (6618.HK), Deqi Pharmaceutical (6996.HK), Rongchang Biotech (9995.HK), WuXi AppTec (2126.HK), Xiansheng Pharmaceutical (2096.HK), Yunding Newray (1952.HK), Jiahe Biotech (6998.HK), Zai Ding Medicine (9688.HK), Ocular Biotech (1477.HK), Yongtai Biotech (6978.HK), Hapu Pharmaceutical (9989.HK), Keping Pharmaceutical (9939.HK), Peijia Medical (9996.HK), Kangfang Biotech (9926.HK), Nuo Cheng Jianhua (9969.HK), Tianjing Biotech (IMAB.NASDAQ), Kanglong Chemical (3759.HK), China Antibody (3681.HK), Dongyao Pharmaceutical (1875.HK), Yasheng Medicine (6855.HK), Fuhong Hanlin (2696.HK), Hansoh Pharmaceutical (3692.HK), Mabotech (2181.HK), Fangda Holdings (1521.HK), Via Biotech (1873.HK), CStone Pharmaceuticals (2616.HK), Junshi Biotech (1877.HK), WuXi AppTec (2359.HK), Xinda Biotech (1801.HK), Hualing Medicine (2552.HK), BeiGene (6160.HK), Gilead Sciences (1672.HK), WuXi AppTec (2269.HK), China Resources Pharmaceutical (3320.HK), Yager Scientific Research Pharmaceutical (2633.HK), Hualing China Medicine (HCM.NASDAQ), Genscript Biotechnology (1548.HK), BBI Life Sciences (1035.HK), Tongyuan Kang Medicine (2410.HK), etc. In terms of the number of filings, the Frost & Sullivan healthcare team maintains an absolute leading position in Hong Kong healthcare IPOs, consistently ranking first in market share from 2018 to 2023.

Since the listing of the first batch of companies on the Sci-tech Innovation Board in July 2019, Frost & Sullivan reports have been widely cited in the prospectuses of leading Sci-tech Innovation Board listed companies in the industry. These include: Zhongyan Co., Ltd. (688716.SH), Zhejiang Rongtai (603119.SH), Optoelectronics Technology Group Co., Ltd. (688450.SH), Jinghe Integration (688249.SH), Wuxi Rilian (688531.SH), Maolai Optics (688502.SH), Kangwe Century (688426.SH), Jinchuan Protein (688137.SH), Novogene Biologics (688428.SH), Aopu Medical Biotechnology (688293.SH), MicroPort Electrophysiology (688351.SH), Mengke Pharmaceutical (688373.SH), Yifang Biologics (688382.SH), Jicui Pharmaceutical (688046.SH), Haichuang Pharmaceutical (688302.SH), Rongchang Biologics (688331.SH), Rendu Biologics (688193.SH), Shouyao Holdings (688197.SH), Heyuan Biologics (688238.SH), Yaxin Security (688225.SH), Xidi Micro (688173.SH), Mawei Biologics (688062.SH), Yahong Medicine (688176.SH), BeiGene (688235.SH), Jiahe Meikang (688246.SH), Dizhe Medicine (688192.SH), Novogene (688105.SH), Chengda Biologics (688739.SH), Geke Micro (688728.SH), Huaxi Biologics (688363.SH), Junshi Biologics (688180.SH), Zhejiang Genomics & Bioinformatics Co., Ltd. (688266.SH), BeiGene (688177.SH), Shenzhou Cells (688520.SH), etc., are considered among the most powerful, professional, and influential industry research institutions in the industry. We hope to work with enterprises to understand industry trends, seize development opportunities, jointly promote innovation and upgrading of China's healthcare industry, and build a healthy future.